You are using IE 8 or below so some features may not work. Please upgrade to a modern browser
Ihr Webbrowser ist veraltet und wird leider nicht in vollem Umfang unterstützt.

Liposomal Formulation of Drugs

Polymun has unique know-how and technology for the development and manufacturing of liposomal formulations.

 

Reference Projects

CUSTOMER/PARTNERPRODUCTSCOPE AT POLYMUNSTATUS
MiNA Therapeutics Ltd.
UK
Liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatment Process development, GMP production
Phase 1 ongoing, UK
Mirna Therapeutics Inc.
USA
Liposomal miRNA MRX34 with Smarticle technology for cancer treatment Process development, GMP production
Phase 1, USA
Dicerna Pharmaceuticals, Inc.
USA
Liposomal formulation of siRNA Process development, GMP production
Preclinical and clinical
Wittycell SAS
(now Abivax) France
Liposomal adjuvant WTCcFormulation and process development, GMP production
Phase 1/2a, South Africa
AC Immune SA
Switzerland
ACI-24, liposomal Alzheimer’s disease vaccine with MPLA adjuvantProcess development, GMP production
Phase 1 ongoing, Europe
EuroNeut-41, EU FP7 project coordinated by Sanofi-Pasteur
France
Liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccineFormulation and process development, GMP production
Phase 1 completed, UK
Signpath Pharma
USA
Liposomal formulation of curcumin for the treatment of cancerFormulation and process development, GMP production
Phase 1 completed, Phase Ib ongoing, Austria
ProNAi Inc.
USA
Liposomal of DNAi PNT100 with Smarticle technology for cancer treatment Process development, GMP production
Phase 2 completed, USA
Dafra Pharma Research and Development bvba
Belgium
OlPC liposomes for the treatment of leishmaniasisFormulation and process development, GMP production
Preclinical
Merck Serono
Germany
Survivac, liposomal cancer vaccineFormulation and process development
Preclincal
Sanochemia Pharmazeutika AG
Austria
Liposomal formulation of galantamine for the treatment of neuropathic painFormulation and process development, GMP production
Phase 1/2a completed, Bulgaria

CUSTOMER/PARTNER

MiNA Therapeutics Ltd.
UK

PRODUCT

Liposomal saRNA MTL-CEBPA with Smarticle technology for cancer treatment

SCOPE AT POLYMUN

Process development, GMP production

STATUS

Phase 1 ongoing, UK

CUSTOMER/PARTNER

Mirna Therapeutics Inc.
USA

PRODUCT

Liposomal miRNA MRX34 with Smarticle technology for cancer treatment

SCOPE AT POLYMUN

Process development, GMP production

STATUS

Phase 1, USA

CUSTOMER/PARTNER

Dicerna Pharmaceuticals, Inc.
USA

PRODUCT

Liposomal formulation of siRNA

SCOPE AT POLYMUN

Process development, GMP production

STATUS

Preclinical and clinical

CUSTOMER/PARTNER

Wittycell SAS
(now Abivax) France

PRODUCT

Liposomal adjuvant WTCc

SCOPE AT POLYMUN

Formulation and process development, GMP production

STATUS

Phase 1/2a, South Africa

CUSTOMER/PARTNER

AC Immune SA
Switzerland

PRODUCT

ACI-24, liposomal Alzheimer’s disease vaccine with MPLA adjuvant

SCOPE AT POLYMUN

Process development, GMP production

STATUS

Phase 1 ongoing, Europe

PRODUCT

Liposomal formulation of HIV membrane protein gp41 and MPLA as HIV vaccine

SCOPE AT POLYMUN

Formulation and process development, GMP production

STATUS

Phase 1 completed, UK

CUSTOMER/PARTNER

Signpath Pharma
USA

PRODUCT

Liposomal formulation of curcumin for the treatment of cancer

SCOPE AT POLYMUN

Formulation and process development, GMP production

STATUS

Phase 1 completed, Phase Ib ongoing, Austria

CUSTOMER/PARTNER

ProNAi Inc.
USA

PRODUCT

Liposomal of DNAi PNT100 with Smarticle technology for cancer treatment

SCOPE AT POLYMUN

Process development, GMP production

STATUS

Phase 2 completed, USA

PRODUCT

OlPC liposomes for the treatment of leishmaniasis

SCOPE AT POLYMUN

Formulation and process development, GMP production

STATUS

Preclinical

CUSTOMER/PARTNER

Merck Serono
Germany

PRODUCT

Survivac, liposomal cancer vaccine

SCOPE AT POLYMUN

Formulation and process development

STATUS

Preclincal

CUSTOMER/PARTNER

Sanochemia Pharmazeutika AG
Austria

PRODUCT

Liposomal formulation of galantamine for the treatment of neuropathic pain

SCOPE AT POLYMUN

Formulation and process development, GMP production

STATUS

Phase 1/2a completed, Bulgaria